Asenapine: A Clinical Overview
J Clin Psychiatry 2011;72(suppl 1):14-18
© Copyright 2016 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
Asenapine is a new, second-generation (atypical) antipsychotic medication with demonstrated efficacy for the acute and maintenance treatment of schizophrenia. It is administered as sublingual tablets in doses of 5 or 10 mg bid. It is well tolerated, with a dropout rate for adverse events similar to that of placebo. Asenapine is associated with a mean weight gain of less than 1 kg over a year and a relatively neutral effect on lipid and glucose levels. It can cause sedation and mild extrapyramidal side effects. Asenapine has a broad receptor affinity profile for most serotonergic, dopaminergic, and adrenergic receptors, with no appreciable affinity for muscarinic receptors. Asenapine may be a helpful treatment option for patients with schizophrenia when weight gain, dyslipidemia, and endocrine abnormalities are a concern.
(J Clin Psychiatry 2011;72[suppl 1]:14–18)
Corresponding author: Department of Psychiatry, Robert R. Sprague Chair in Brain Imaging, Director, UCI Brain Imaging Center, University of California, Irvine, 5251 California Ave, Ste 240, Irvine, CA (email@example.com).
© Copyright 2011 Physicians Postgraduate Press, Inc.